Forte Biosciences Inc., a clinical-stage biopharmaceutical company, has announced its financial results for the first quarter of 2025. The company reported a net loss of $15.656 million for the quarter, compared to a net loss of $7.420 million during the same period in 2024. The comprehensive loss also increased to $15.667 million from $7.426 million in the prior year. Research and development expenses saw a significant increase, rising to $12.7 million in Q1 2025, up from $4.4 million in the first quarter of 2024. This rise was attributed to ongoing clinical trials and additional non-cash stock-based compensation of $0.7 million. General and administrative expenses remained relatively stable at $3.432 million, compared to $3.451 million in the previous year. Forte Biosciences ended the first quarter of 2025 with $45.9 million in cash and cash equivalents, an increase from $22.244 million at the end of December 2024. This financial position is supported by the 6.6 million shares of common stock and 4.8 million pre-funded warrants outstanding as of March 31, 2025. The company also provided a clinical update, highlighting progress in its trials for FB102. The company is anticipating topline data from the FB102 celiac disease trial and has already dosed the first patient in the FB102 vitiligo trial. CEO Paul Wagner stated that 2025 is expected to be an eventful year for Forte, with further validation of FB102's potential anticipated.